Performance of a Fluorescence Immunoassay-Based Interferon-Gamma Release Assay for Latent Tuberculosis Infection.

Authors

Eungjun Yoon, Jae Joon Lee, Hyejin Ryu, Ajoy Kumar Verma, Ashish Ranjan, Lokender Kumar, Rajesh Kumar, Gavish Kumar, Ankita Dey, Tae Yeul Kim, Minjeong Nam

Published in

Clinical laboratory. Volume 72. Issue 9. Pages 1919-1924. Sep 01, 2026.

Abstract

Latent tuberculosis infection (LTBI) diagnosis is crucial for controlling tuberculosis (TB). Interferon-gamma release assay (IGRA) diagnoses LTBI by measuring interferon-gamma produced by TB antigen-stimulated T-cells. In this study, we evaluated the clinical performance of AFIAS IGRA-TB (Boditech Med, Inc.).
A total of 200 subjects, including those without known risk factors for TB infection, those with known TB contact, and those with active TB, were analyzed using both AFIAS IGRA-TB and QuantiFERON-TB Gold In-Tube (QFT-GIT; Qiagen) according to the manufacturers' instructions.
The positive, negative, and overall percent agreements between AFIAS IGRA-TB and QFT-GIT were 88.2% (95% confidence interval [CI]: 76.6 - 94.5%), 95.4% (95% CI: 90.4 - 97.9%), and 93.4% (95% CI: 88.8 - 96.2%), respectively. Cohen's kappa coefficient was 0.84, indicating excellent agreement.
AFIAS IGRA-TB demonstrated equivalent clinical performance to QFT-GIT. Given its ease of use, minimal reliance on trained personnel or complex equipment, and rapid turnaround time, AFIAS IGRA-TB has the potential to serve as an alternative test for diagnosing LTBI and active TB in resource-limited settings.

PMID:
42733985
Bibliographic data and abstract were imported from PubMed on 14 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.